Inventiva S.A. Issues 201 Royalty Certificates to Investors

TL;DR

Inventiva sold 201 royalty certificates on July 17th, raising capital via a private placement.

AI Summary

On July 17, 2024, Inventiva S.A. entered into Royalty Certificate Subscription Agreements to issue and sell 201 royalty certificates to certain investors. This transaction, exempt from registration under the Securities Act of 1933, will provide holders with specific rights.

Why It Matters

This issuance of royalty certificates could impact Inventiva's future cash flows and its relationship with investors, potentially affecting its financial flexibility.

Risk Assessment

Risk Level: medium — The issuance of royalty certificates represents a form of financing that could have implications for future revenue streams and investor relations.

Key Numbers

• 201 — Royalty Certificates (Number of royalty certificates issued in the transaction.)

Key Players & Entities

• Inventiva S.A. (company) — Registrant
• July 17, 2024 (date) — Date of subscription agreements
• 201 (number) — Number of royalty certificates
• Royalty Certificate Subscription Agreements (document) — Agreements for issuing royalty certificates
• Royalty Certificates (financial_instrument) — Securities being issued

FAQ

Filing Documents

• tm2419707d1_6k.htm (6-K) — 25KB
• tm2419707d1_ex99-1.htm (EX-99.1) — 268KB
• tm2419707d1_ex99-2.htm (EX-99.2) — 39KB
• tm2419707d1_ex99-2img01.jpg (GRAPHIC) — 5KB
• tm2419707d1_ex99-2img02.jpg (GRAPHIC) — 24KB
• 0001104659-24-080660.txt ( ) — 373KB

Forward-Looking Statements

Forward-Looking Statements This report on Form 6-K contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this Form 6-K are forward-looking statements. These statements include, but are not limited to, the timing and completion of the Transaction, the development and commercialization of lanifibranor and achievement of any sales related thereto, payment of royalties, the Registrant's anticipated future performance and the expected use of proceeds from the Transaction. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "would", "could", "might", "should", and "continue" and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond the Registrant's control. There can be no guarantees with respect to pipeline product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by the Registrant or its partners will be reached on their expected timeline, or at all. Actual results may turn out to be materially different from the anticipated future results,

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inventiva S.A. Date: July 18, 2024 By: /s/ Frédéric Cren Name Frédéric Cren Title: Chief Executive Officer

View Full Filing

View this 6-K filing on SEC EDGAR